Investor Presentaiton
TLX591 differentiation
Potential advantages with PSMA antibody approach
Efficacy
Potential for improved overall survival (OS) in advanced metastatic disease, with
40+ months OS reported to date1
For personal use only
Patient comfort
Reduced potential for off-target side-effects: dry eye, xerostomia (salivary gland
ablation), back pain (ganglia irradiation)
Patient-centric
regimen
Short treatment duration/significantly fewer hospital visits - two weeks total
vs. 36 weeks, supports close supervision by medical oncology
$
Cost effective
Significantly lower 177 Lu isotope requirements with commensurate reduction in
COGS, expected to also be available in "cold kit" format
1. Tagawa et al, Cancer 2019.
Telix Pharmaceuticals Limited (ASX: TLX)
33
33
TELIX
PHARMACEUTICALSView entire presentation